Human Cytochrome P450 1A1 Adapts Active Site for Atypical Nonplanar Substrate

被引:15
作者
Bart, Aaron [1 ]
Takahashi, Ryan H. [4 ]
Wang, Xiaojing [5 ]
Scott, Emily E. [1 ,2 ,3 ]
机构
[1] Univ Michigan, Program Biophys, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA
[4] Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA
[5] Genentech Inc, Dept Discovery Chem, San Francisco, CA 94080 USA
基金
美国国家卫生研究院;
关键词
BINDING; CAVITIES; FEATURES; ENZYMES; DRUG;
D O I
10.1124/dmd.119.089607
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The human cytochrome P450 1A1 (CYP1A1) is well known for chemical activation of procarcinogens and often has a substrate scope of small and highly planar compounds. Substrates deviating from these characteristics are certainly known, but how these larger and nonplanar substrates are accommodated and oriented within the CYP1A1 active site is not understood. Herein a new X-ray structure of CYP1A1 bound to the pan-Pim kinase inhibitor GDC-0339 reveals how the CYP1A1 active site cavity is reconfigured to bind larger and nonplanar compounds. The shape and size of the cavity are controlled by structural elements in the active site roof, with major changes in the conformation of the F helix break and relocation of Phe224 from the active site to the protein surface. This altered CYP1A1 active site architecture is consistent with the proposed mechanism for CYP1A1 generation of an unusual aminoazepane-rearranged metabolite for this substrate. SIGNIFICANCE STATEMENT Cytochrome P450 1A1 metabolizes drugs, procarcinogens, and toxins and although previous structures have revealed how its stereotypical planar, aromatic compounds are accommodated in the CYP1A1 active site, this is not the case for flexible and nonplanar compounds. The current work determines the X-ray structure of CYP1A1 with such a flexible, nonplanar Pim kinase inhibitor, revealing significant modification of the CYP1A1 roof that accommodate this preclinical candidate and support an unusual intramolecular rearrangement reaction.
引用
收藏
页码:86 / 92
页数:7
相关论文
共 25 条
[1]   PHENIX: a comprehensive Python']Python-based system for macromolecular structure solution [J].
Adams, Paul D. ;
Afonine, Pavel V. ;
Bunkoczi, Gabor ;
Chen, Vincent B. ;
Davis, Ian W. ;
Echols, Nathaniel ;
Headd, Jeffrey J. ;
Hung, Li-Wei ;
Kapral, Gary J. ;
Grosse-Kunstleve, Ralf W. ;
McCoy, Airlie J. ;
Moriarty, Nigel W. ;
Oeffner, Robert ;
Read, Randy J. ;
Richardson, David C. ;
Richardson, Jane S. ;
Terwilliger, Thomas C. ;
Zwart, Peter H. .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2010, 66 :213-221
[2]   Structures of human cytochrome P450 1A1 with bergamottin and erlotinib reveal active-site modifications for binding of diverse ligands [J].
Bart, Aaron G. ;
Scott, Emily E. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (50) :19201-19210
[3]  
DeLano W.L., 2017, PYMOL MOL GRAPHICS S
[4]   Key Residues Controlling Binding of Diverse Ligands to Human Cytochrome P450 2A Enzymes [J].
DeVore, N. M. ;
Smith, B. D. ;
Wang, J. L. ;
Lushington, G. H. ;
Scott, E. E. .
DRUG METABOLISM AND DISPOSITION, 2009, 37 (06) :1319-1327
[5]   Features and development of Coot [J].
Emsley, P. ;
Lohkamp, B. ;
Scott, W. G. ;
Cowtan, K. .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 2010, 66 :486-501
[6]   Structural Diversity of Eukaryotic Membrane Cytochrome P450s [J].
Johnson, Eric F. ;
Stout, C. David .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (24) :17082-17090
[7]  
Jungmann N, 2019, 12 INT SOC STUD XEN, P55
[8]   DETECTION, DELINEATION, MEASUREMENT AND DISPLAY OF CAVITIES IN MACROMOLECULAR STRUCTURES [J].
KLEYWEGT, GJ ;
JONES, TA .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :178-185
[9]   Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile [J].
Li, Xiaohai ;
Kamenecka, Theodore M. ;
Cameron, Michael D. .
DRUG METABOLISM AND DISPOSITION, 2010, 38 (07) :1238-1245
[10]   Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities [J].
Li, Xiaohai ;
Kamenecka, Theodore M. ;
Cameron, Michael D. .
CHEMICAL RESEARCH IN TOXICOLOGY, 2009, 22 (10) :1736-1742